PDF
Citation
Print
THE BRIEF HISTORY OF CHINESE CYTOPATHOLOGY
In the 1950s, Dr. Dawang Yang returned to China to start cervical cytology after completing her academic studies in the United States [1,2]. She began the practice of Papanicolaou cervical smear classification and a cervical cancer screening program in Peking Union Hospital [3]. Vaginal Cytopathology was published by Dr. Dawang Yang in 1952, which was the first Chinese cytology book and marked the start of modern cytopathology in China.
Esophageal balloon cytology was developed for screening of esophageal cancer, and a series of English publications from China made it well known around the world since the 1960s [4-6]. Fine-needle aspiration (FNA) was applied first on the body surface and then in deep organs in the 1970–80s. Bone tumor cytodiagnosis was developed by hematologist and cytologist Dr. Xiaojing Peng [7], who published the first Chinese FNA book, Atlas of Clinical Cytology, in 1972. The Chinese Academy of Cytology was founded and the first National Clinical Cytology Conference was held in 1985, which was a milestone of cytology in China [8].
New ancillary techniques such as immunocytochemistry, flow cytometry and DNA alteration analysis were applied in addition to cytopathology starting at the end of 1980s [1,9]. Liquidbased cytology was initially applied to the cervical smear in the 1990s and greatly improved slide quality and accuracy of diagnosis. The Bethesda System (TBS) for reporting cervical cytology replaced Papanicolaou classification, and computer-aided analysis started to play a role.
Cytology has started to play a more prominent role in diagnosis, and quality control of cytology has further improved during the recent 10 years. The Cytology Operational Manual and Quality Control Standards were proposed by the Cytology Section of the Chinese Pathology Association in 2007. A Cytology Quality Control Expert Team was formed in 2010 to supervise clinical diagnosis and academic training, and international exchanges became more popular.
THYROID FINE-NEEDLE ASPIRATION IN CHINA
Thyroid FNA was primarily developed in endocrinology departments and became popular around China in the 1970–80s. Wright’s stain was originally the most popular staining method and was founded by hematologist and cytologist Dr. Xiaojing Peng. In 1987, a national conference posited that FNA cytology should be a branch of pathology, and the cytologist should have a background of surgical pathology. Thyroid FNA began to increase in popularity in some pathology departments, and hematoxylin and eosin staining was applied because it increased the ease of comparing histological samples. Ultrasound-guided thyroid FNA (UG-FNA) became popular gradually, and molecular examination was applied as an additional diagnostic method for papillary thyroid carcinoma (PTC).
MOLECULAR TESTING OF THYROID FINE-NEEDLE ASPIRATION IN CHINA
Next-generation sequencing was proposed recently to improve the diagnosis of thyroid FNA specimens with indeterminate cytology; however, it is expensive and not well accepted in clinics in China [10-12]. BRAFV600E mutation analysis was recommended by American Thyroid Association (ATA) guidelines as an auxiliary diagnostic method for thyroid FNA cytology [13,14]. The amplification refractory mutation system is efficient and inexpensive and is the most popular method for detection of BRAFV600E mutation in China. Zhang et al. [14] recently studied the Thyroid Imaging Reporting and Data System (TIRADS), Bethesda System for Reporting Thyroid Cytopathology (BSRTC), and the BRAFV600E mutation analysis as molecular tools in diagnosing thyroid carcinoma. The TIRADS was applied for selecting patients for FNA biopsy and BRAFV600E mutation analysis. They found that BRAFV600E mutation detection had the best sensitivity, specificity, and accuracy among the three methods. Both TIRADS and BRAFV600E detection showed increased sensitivity and accuracy when combined with BSRTC. Of all methods, a combination of BSRTC and BRAFV600E mutation detection demonstrated the best diagnostic efficiency [14].
PRACTICE IN QILU HOSPITAL, SHANDONG PROVINCE
Thyroid FNA is not yet well accepted in China, and most general hospitals use frozen sectioning as a diagnostic method instead of thyroid FNA. Some hospitals began to use UG-FNA around the 1990s, along with diagnostic frozen sectioning. UG-FNA is more popular in local hospital than in general hospital. Qilu Hospital is one of the epitomes of thyroid FNA in China, and began performing non-ultrasound guided thyroid FNA cytology in the endocrinology department (including both FNA and cytopathology) in 1991. UG-FNA for thyroid nodules began in 2014, the pathologist began to sign the thyroid FNA report instead of the endocrinologist.
Another point to note is that most Chinese patients choose to undergo diagnostic surgery in the presence of unfavorable clinical and ultrasonographic features, no matter what the size is. There were 2,612 thyroid surgeries, all with a rapid intraoperative pathological diagnosis using diagnostic frozen section, from 2015 to 2016 in our department [15]. However, only 791 thyroid FNA patients (30.3%) underwent thyroid surgery. This indicates that there is still ample opportunity for advancement of thyroid FNA in China. Thyroid FNA should be performed to avoid unnecessary surgery for benign thyroid lesions.
Materials and methods
A retrospective study was conducted of all patients with UG-FNA between January 2014 and April 2017 in Qilu Hospital, Shandong University. All patients had available thyroid ultrasound records. Approval was obtained from Qilu Hospital ethics committee, and the patients provided written informed consent. Criteria for FNA were those of Dr. Zhu et al. [16] Hematoxylin and eosin–stained slides of all tumors were reviewed by three pathologists (Z.L., X.Z., and P.S.). Diagnosis was made according to BSRTC, as shown in Table 1; the only exception was that the cystic-only group was classified into the benign group rather than as nondiagnostic [17].
Criteria for surgical treatment
Thyroid surgery was recommended to all patients with suspicion of malignancy or malignancy reports. Diagnostic surgery and frozen sectioning were suggested for patients with high-risk clinical or ultrasonographic features. Patients with at least one atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) report were recommended for repeat FNA or diagnostic partial thyroid lobectomy. Once malignant histological evidence was demonstrated by frozen section, lobectomy was performed for papillary thyroid microcarcinoma (PTMC), and total thyroidectomy was usually performed for tumors larger than 1 cm with lymph node metastasis. Patients refusing surgical treatment or with high surgical risk were recommended for clinical and ultrasonographic follow-up. Patients with benign FNA cytology diagnosis underwent surgery only when there were clinical symptoms. Patients with nondiagnostic reports were recommended for repeat FNA or clinical and ultrasonographic follow-up.
Results and discussion
As shown in Table 1, FNA performed on 2838 thyroid nodules showed 3.6% nondiagnostic specimens, 44.7% benign nodules, 7.1% indeterminate (6.9% AUS/FLUS and 0.2% follicular neoplasm or suspicious for a follicular neoplasm [FN/SFN]), 14.1% suspicious for malignancy, and 30.6% positive for malignancy. The correlation between FNA cytology and histological diagnosis is shown in Table 2.
The most common FNA diagnosis rendered in our practice was benign, which was nearly the same as the Bethesda expected incidence. Ninety cases of benign nodules were followed with clinical management because of high-risk ultrasound results, 31 cases were proved to be PTMC less than 5 mm in diameter, and one case was mucosa-associated B-cell lymphoma. This positive rate of FNA for PTMC less than 5 mm is worse than other practices in China, probably due to the unskillful operation of the UG-FNA for thyroid nodules less than 5 mm in diameter [13]. Nodules less than 1 cm in size should be followed up closely according to the ATA guideline [13,18], which is not well accepted in China. Two cases of FN/SFN were proved to be follicular carcinoma (FTC), and one was proved to be follicular tumor of uncertain malignant potential, which indicated the difficulty to cytologically differentiate atypical follicular adenoma from minimally invasive FTC [19].
Fifteen of 21 cases of AUS/FLUS were proved to be histologically malignant. These results were different from another study in China, as shown in Table 2. The risks of malignancy (ROMs) of AUS/FLUS and suspicious for malignancy were nearly the same, likely due to the different diagnostic criteria for the cytopathologist; when there are less than 30 atypical cells, we make the diagnosis of “AUS/FLUS” instead of “suspicious of malignancy.” This is an attempt by the pathologist to suggest a repeat FNA instead of diagnostic surgery for such lesions. In the suspicious of malignancy group, there were three cases of hyalinizing trabecular tumor (HTT). As shown in Fig. 1A and B, there were obvious pseudoinclusions in the cell smear of HTT. Although the nuclear clearing is not conspicuous, the cells were of variable size with nuclear atypia and nuclear grooves, which led to the over-diagnosis of PTC. However, filament-like hyalinizing material was found around the tumor cells, suggesting the possibility of HTT, which is classified as borderline tumor in the new World Health Organization classification of endocrine tumors [20].
Patients in the “nondiagnostic” group will not undergo immediate operation, and repeat FNA is recommended after 3-month follow-up in our practice. Only six cases were followed by operation, and none of them was malignant. The ROM of this category was different from that of another practice in China and Dr. Ali’s practice in the United Sates [14,21]. Routine BRAFV600E mutation analysis was applied to all FNA samples in Dr. Zhang’s practice, which could improve the accuracy rate of FNA [14]. This is likely one reason that the operation rate was low in our practice for patients in the nondiagnostic category. Another reason could be a significant number of patients went to another hospital instead of our hospital because of bed tension or economic issue. Meanwhile, Dr. Zhang’s result suggests that routine BRAFV600E mutation analysis is necessary to improve the efficiency, sensitivity, and specificity of thyroid FNA cytology.
Above all, thyroid FNA is an important part of preoperative diagnosis, but it is still in an early stage in China compared with histopathology. Ultrasound, radiology, physical presentation, and molecular features of thyroid nodules are critical to achieve an accurate cytologic diagnosis. The last decade has witnessed rapid development of thyroid FNA in China. The next decade will offer exciting opportunities, and international exchange and cooperation are necessary for cytologists to develop thyroid FNA to a higher level.
XML Download